

# Napsin A

Concentrated and Prediluted Monoclonal Antibody  
902-388-082622

**BIOCARE**  
M E D I C A L

Available Product Formats				
Format	Catalog Number	Description	Dilution	Diluent
Concentrate	ACR 388 AK, CK	0.1, 1.0 mL	1:100	Renoir Red
Predilute	APR 388 AA	6.0 mL	Ready-to-use	N/A
UltraLine – For BenchMark	AVR 388 G	6.0 mL	Ready-to-use	N/A
Q Series– For Leica BOND-III	ALR 388 G7	7.0 mL	Ready-to-use	N/A

## Intended Use:

For Research Use Only. Not for use in diagnostic procedures.

## Summary and Explanation:

Napsin A is a pepsin-like aspartic proteinase. It is expressed in type II pneumocytes and in adenocarcinomas of the lung and kidney (2). Studies have shown that Napsin A is both more sensitive and specific than TTF-1. When compared to TTF-1, Napsin A showed a higher specificity (94.3%) for adenocarcinoma in non-small cell lung carcinoma as compared to TTF-1 (76.1%) (4). Unlike TTF-1, Napsin A is positive in some renal cell carcinomas (RCC). Several studies have shown that Napsin A was positive in 83%-90.7% of primary lung adenocarcinomas (1-3). Other neoplastic tissues such as ovarian cancers show low expression with different staining patterns from that of primary lung cancer which shows granular cytoplasmic staining in tumor cells. In studies comparing TTF-1 and SP-A, Napsin A stained more tumor cells and a higher percentage of lung adenocarcinomas than either of these antibodies.

## Principle of Procedure:

Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. After labeling the antigen with a primary antibody, a one-step or two-step detection procedure can be applied. A one-step procedure will feature an enzyme labeled polymer that binds the primary antibody. A two-step procedure will feature a linker antibody added to bind to the primary antibody. An enzyme-labeled polymer is then added to bind the linker antibody. These detections of the bound antibodies are evidenced by a colorimetric reaction.

**Source:** Mouse monoclonal

**Species Reactivity:** Human, others not tested

**Clone:** TMU-Ad 02

**Isotype:** IgG1

**Epitope/Antigen:** Synthetic peptide of a part of the N-terminus of human Napsin A

**Cellular Localization:** Cytoplasmic

**Positive Tissue Control:** Lung adenocarcinoma

**Protein Concentration:** Call for lot specific Ig concentration.

## Known Applications:

Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

**Supplied As:** Buffer with protein carrier and preservative  
Renoir Red (BRR904)

## Storage and Stability:

Store at 2°C to 8°C. The product is stable to the expiration date printed on the label, when stored under these conditions. Do not use after expiration date. Diluted reagents should be used promptly; any remaining reagent should be stored at 2°C to 8°C.

## Staining Protocol Recommendations (intelliPATH FLX® and manual use):

**Peroxide Block:** Block for 5 minutes with Peroxidized 1.

**Pretreatment:** Perform heat retrieval using Diva Decloaker. Refer to the Diva Decloaker data sheet for specific instructions.

**Protein Block (Optional):** Incubate for 5-10 minutes at RT with Background Punisher.

**Primary Antibody:** Incubate for 30 minutes at RT.

**Probe:** Incubate for 10 minutes at RT with a secondary probe.

**Polymer:** Incubate for 10-20 minutes at RT with a tertiary polymer.

## Staining Protocol Recommendations (intelliPATH FLX and manual use) Cont'd:

**Chromogen:** Incubate for 5 minutes at RT with Biocare's DAB - OR - Incubate for 5-7 minutes at RT with Warp Red.

## Counterstain:

Counterstain with hematoxylin. Rinse with deionized water. Apply Tacha's Bluing Solution for 1 minute. Rinse with deionized water.

## Technical Note:

This antibody, for intelliPATH FLX and manual use, has been standardized with MACH 4 detection system. Use TBS for washing steps.

## Staining Protocol Recommendations (Ventana BenchMark ULTRA):

AVR388 is intended for use with the BenchMark ULTRA. Refer to the User Manual for specific instructions for use. Recommended protocol parameters are as follows:

**Template/Detection:** OptiView DAB IHC

**Pretreatment Protocol:** CC1 32 minutes

**Peroxidase:** Pre-Primary Peroxidase Inhibitor

**Primary Antibody:** 32 minutes, 36°C

## Staining Protocol Recommendations (Q Series – For Leica BOND-III):

ALR388 is intended for use with the Leica BOND-III. Refer to the User Manual for specific instructions for use. Recommended protocol parameters are as follows:

**Protocol Name:** IHC Protocol F

**Detection:** Bond Polymer Refine

**HIER:** 20 min with ER2

**Peroxide Block:** 5 min

**Marker (Primary Antibody):** 15 min

**Post Primary:** 8 min

**Polymer:** 8 min

**Mixed DAB Refine:** 10 min

**Hematoxylin:** 5 min

## Limitations:

This product is provided for Research Use Only (RUO) and is not for use in diagnostic procedures. Suitability for specific applications may vary and it is the responsibility of the end user to determine the appropriate application for its use.

## Precautions:

1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN<sub>3</sub>) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (5)

2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come in contact with sensitive areas, wash with copious amounts of water. (6)

3. Microbial contamination of reagents may result in an increase in nonspecific staining.



60 Berry Drive  
Pacheco, CA 94553  
USA

Rev. 062117

Tel: 800-799-9499 | www.biocare.net | Fax: 925-603-8080

## Napsin A

Concentrated and Prediluted Monoclonal Antibody  
902-388-082622

**BIOCARE**  
M E D I C A L

### Precautions Cont'd:

4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.
5. Do not use reagent after the expiration date printed on the vial.
6. The SDS is available upon request and is located at <http://biocare.net>.

### Technical Support:

Contact Biocare's Technical Support at 1-800-542-2002 for questions regarding this product.

### References:

1. Hirano T, *et al.* Usefulness of TA02 (Napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. *Lung Cancer*. 2003 Aug; 41 (2):155-62.
2. Ueno T, Linder S, Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. *Br J Cancer*. 2003 Apr 22; 88(8):1229-33.
3. Suzuki A, *et al.* Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. *Pathol Res Pract*. 2005;201 (8-9):579-86.
4. Dejmek A, *et al.* Napsin A (TA02) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma cells in pleural effusions. *Diagn Cytopathol*. 2007 Aug;35(8):493-7.
5. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts."
6. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.

Ultraline antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare antibodies by Ventana Medical Systems, Inc or Roche. Biocare, Ventana and Roche are not affiliated, associated or related in any way. Ventana®, BenchMark®, ultraView and OptiView are trademarks of Roche.

Q Series antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare antibodies by Leica Biosystems. Biocare and Leica Biosystems are not affiliated, associated or related in any way. Leica, Leica Biosystems, BOND-MAX and BOND-III are trademarks of Leica Biosystems.



60 Berry Drive  
Pacheco, CA 94553  
USA

Rev. 062117

Tel: 800-799-9499 | [www.biocare.net](http://www.biocare.net) | Fax: 925-603-8080